Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Acr-2316
Specific Advanced Solid Tumors
Phase I
Recruiting
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Oct 23, 2024
―
Gemcitabine, Acr-368, Oncosignature
Endometrial Adenocarcinoma
Phase II
Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Aug 29, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Acrivon Therapeutics, Inc. (ACRV) have in its pipeline
ACRV is currently developing the following drugs: Acr-2316, Gemcitabine, Acr-368, Oncosignature. These drug candidates are in various stages of clinical development as the company works toward FDA approval.